ClinicalTrials.gg
Active, not recruitingNCT06956170DREAMM 8Updated Jun 12, 2026Results posted

All Japanese Population: Belantamab Mafodotin Plus Pomalidomide and Dexamethasone (Pd) Versus Bortezomib Plus Pd in Relapsed/Refractory Multiple Myeloma

A Phase 3 interventional study of Belantamab mafodotin and Pomalidomide in Multiple Myeloma, sponsored by GlaxoSmithKline. Active, not recruiting at 13 sites in Japan. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-06-12.

Sponsored by GlaxoSmithKline · Phase 3, Interventional, and Treatment

From the registry’s dates

  • Registered 3 years 2 months after the study started (first participant enrolled Feb 2022, registered Apr 2025).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
21
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 49 studies testing belantamab mafodotin in Multiple Myeloma — 15 open to participants now, 35 under way, 8 of them phase 3. belantamab mafodotin · Multiple Myeloma.

Enrollment
34th of 49
21 · median 50
Started
2022
with 9 others
Phase 3
9 of 49
2 open now
Primary completion
2024-05
later than 5 of 34 live
Registered
38th of 49
by date
Lead sponsor
24 of 49
GlaxoSmithKline

Among the 49 studies testing belantamab mafodotin in Multiple Myeloma, this one is the 34th largest by enrollment, is one of 10 that started in 2022, is one of 9 in phase 3, reaches primary completion later than 5 of the 34 other live ones, and was the 38th registered.

Multiple Myeloma

3,763 studies on the registry are indexed under Multiple Myeloma; 770 are open to participants now.

Browse Multiple Myeloma studies →

Open to participants now

15 of the 49 studies testing belantamab mafodotin in Multiple Myeloma are open now, in 12 countries. Recruiting first, the newest first:

10 more — sign in →

By country, each count listing its studies:

All 15 open studies →

About belantamab mafodotin

belantamab mafodotin: first FDA approval 2020 (Blenrep), first EMA approval 2020. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 585 Multiple Myeloma studies recruiting now, 430 (74%) set no upper age limit and 106 (18%) stop at 75 or younger; 36 take children under 18; 24 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 49 studies testing belantamab mafodotin in Multiple Myeloma, or all of them as a file.
02

Study summary

This study will evaluate the efficacy and safety of belantamab mafodotin in combination with pomalidomide and dexamethasone compared with that of combination of pomalidomide, bortezomib and dexamethasone in Japanese participants with relapsed/refractory multiple myeloma (RRMM).

03

Conditions studied

  • Multiple Myeloma

Browse trials for

Keywords

  • Japan population
  • Belantamab Mafodotin
  • Relapsed/Refractory Multiple Myeloma
  • Pomalidomide
  • Dexamethasone
  • Bortezomib
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Capable of giving signed .
  • Male or female, 18 years or older.
  • Have a confirmed diagnosis of multiple myeloma (MM) as defined by the International Myeloma Working Group (IMWG) criteria.
  • (ECOG) performance status of 0 to 2.
  • Have been previously treated with at least 1 prior line of MM therapy including a lenalidomide-containing regimen and must have documented disease progression during or after their most recent therapy. (Participants treated with lenalidomide ≥10 mg daily for at least 2 consecutive cycles are eligible).
  • Must have at least 1 aspect of defined as one of the following;

    1. Urine M-protein excretion greater than or equal to (≥)200 milligrams (mg) per 24-hour, or
    2. Serum M-protein concentration ≥0.5 grams/deciliters (g/dL) (≥5.0 g/liter [L]), or
    3. Serum free light chain (FLC) assay: involved FLC level ≥10 mg/dL (≥100 mg/L) and an abnormal serum free light chain ratio (less than [\<]0.26 or greater than [>]1.65) only if participant has no measurable urine or serum M spike.
  • Have undergone stem cell transplant (ASCT) or are considered transplant ineligible. Participants with a history of ASCT are eligible for study participation provided the following eligibility criteria are met: a. ASCT was >100 days prior to the first dose of study medication. b. No active bacterial, viral, or fungal infection(s) present
  • All prior treatment-related toxicities (defined by National Cancer Institute [NCI-CTCAE] version 5.0) must be less than or equal to (≤)Grade 1 at the time of enrolment, except for alopecia.
  • Adequate organ system functions as mentioned in the protocol.
  • Male and female participants agree to abide by protocol-defined requirements.
  • In Japan, participants who are hepatitis B surface antigen (HbsAg)- (e.g. HBsAb+/HbsAg-, HBcAb+/HbsAg-, HBcAb+/HBsAb+/HbsAg-) are eligible for inclusion in this study if hepatitis B virus (HBV) DNA is undetectable. A patient with HBsAg+ is eligible if HBV DNA is undetectable after assessing hepatitis B e antigen (HBeAg), hepatitis B e antibody (HBeAb) and HBV DNA, and if a hepatologist agrees with the participation into this study.

Exclusion criteria

Exclusion Criteria:

  • Active plasma cell leukemia, symptomatic amyloidosis or active polyneuropathy, organomegaly, endocrinopathy, monoclonal plasma proliferative disorder, and skin changes (POEMS) syndrome at the time of screening.
  • Prior SCT.
  • Systemic anti-myeloma therapy (including chemotherapy and systemic ) within 14 days or five half-lives (whichever is shorter) preceding the first dose of study drug; prior treatment with a monoclonal antibody drug within 30 days of receiving the first dose of study drugs.
  • Plasmapheresis within 7 days prior to the first dose of study drug.
  • Received prior treatment with or intolerant to pomalidomide.
  • Received prior Beta cell maturation antigen (BCMA) targeted therapy.
  • Intolerant to bortezomib or to bortezomib (for example; participant experienced progressive disease during treatment, or within 60 days of completing treatment, with a bortezomib-containing regimen of 1.3 mg/meter square [m\^2] twice weekly).
  • Evidence of cardiovascular risk including any of the following;

    1. Evidence of current untreated arrhythmias, including clinically significant abnormalities including second degree (Mobitz type II) or third degree atrioventricular (AV) block.
    2. Recent history within (3 months of screening) of myocardial infarction, acute coronary syndromes (including unstable angina), coronary angioplasty, or stenting or bypass grafting .
    3. Class III or IV heart failure as defined by the (NYHA) functional classification system
    4. Uncontrolled hypertension.
  • Any major surgery within the last 4 weeks.
  • Previous or concurrent invasive other than multiple myeloma, except:

    1. The disease must be considered medically stable for at least 2 years; or
    2. The participant must not be receiving active therapy, other than hormonal therapy for this disease.
  • Known immediate or delayed reaction or idiosyncratic reaction to belantamab mafodotin or drugs chemically related to belantamab mafodotin, or any of the components of the study treatment.
  • Evidence of active mucosal or internal bleeding.
  • Cirrhosis or current unstable liver or biliary disease per investigator assessment defined by the presence of ascites, encephalopathy, coagulopathy, hypoalbuminemia, esophageal or gastric varices, persistent jaundice.
  • Active infection requiring treatment.
  • Known or active (HIV) infection, or will be excluded unless the protocol-defined criteria are met.
  • Presence of active renal conditions (such as infection, severe renal impairment requiring dialysis or any other condition that could affect participant's safety).
  • Ongoing Grade 2 peripheral neuropathy with pain within 14 days prior to randomization or ≥Grade 3 peripheral neuropathy.
  • Active or history of venous and arterial thromboembolism within the past 3 months.
  • to or unwilling to undergo protocol-required anti-thrombotic prophylaxis.
  • Current corneal disease except for mild punctate keratopathy.
  • Any serious and/or unstable pre-existing medical, psychiatric disorder or other conditions (including laboratory abnormalities) that could interfere with participant's safety, obtaining or compliance to the study procedures.
  • Pregnant or lactating female.
Terms in these criteria, in plain language(17)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

Allogeneic and autologous transplant

Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.

CTCAE grade

The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.

1
Mild.
2
Moderate.
3
Severe.
4
Life-threatening.
5
Death due to the event.

“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
21 participants (actual)

Study arms

  • Experimental
    Belantamab mafodotin plus Pomalidomide and Dexamethasone

    Drug: Belantamab mafodotin · Drug: Pomalidomide · Drug: Dexamethasone

  • Active comparator
    Bortezomib plus Pomalidomide and Dexamethasone

    Drug: Pomalidomide · Drug: Dexamethasone · Drug: Bortezomib

Interventions

  • Humanized anti-B-cell maturation antigen (BCMA) antibody/drug conjugate will be administered.

  • Immunomodulatory drug (IMiD) will be administered.

  • Synthetic glucocorticoid with anti-tumor activity will be administered.

  • Proteasome Inhibitor will be administered.

06

What researchers measure

Primary outcomes

  1. Progression-Free Survival (PFS)

    PFS is defined as time from randomization until earliest date of disease progression (PD), determined by Independent Review Committee (IRC), according to the International Myeloma Working Group (IMWG) Response Criteria, or death due to any cause. PD is defined as increase of \>=25% from lowest value in \>=1 of following (serum M-protein \[absolute increase \>=0.5 grams per deciliter {g/dL}\]; serum M-protein increase \>=1g/dL \[when lowest M-protein \>=5g/dL\]; urine M-protein \[absolute increase \>=200 milligrams per 24 hours {mg/24h}\]; participants without measurable serum \& urine M-protein levels, difference between involved \& uninvolved serum free light chains (sFLC) levels \[absolute increase \>10mg/dL\]; appearance of new lesion,\>=50% increase from nadir in Sum of the products of the maximal perpendicular diameters of measured lesions (SPD) of \>1 lesion, or \>=50% increase in longest diameter of previous lesion \>1 centimeter (cm) in short axis.

    Time frame: Up to approximately 120 weeks

Secondary outcomes

  1. Overall Survival (OS)

    Overall Survival (OS) defined as the interval of time from randomization to the date of death due to any cause.

    Time frame: Up to approximately 407 weeks

  2. Duration of Response (DoR)

    Duration of Response (DoR) defined as the time from first documented evidence of partial response (PR) or better until progressive disease (PD) or death due to any cause. Response will be based on IRC-assessment per IMWG criteria.

    Time frame: Up to approximately 407 weeks

  3. Minimal Residual Disease (MRD) Negativity Rate

    MRD negativity rate defined as the percentage of participants who achieve MRD negative status (as assessed by NGS at 10\^5 threshold) at least once during the time of confirmed CR or better response based on IRC-assessment per IMWG.

    Time frame: Up to approximately 407 weeks

  4. Overall Response Rate (ORR)

    ORR is defined as the percentage of participants with a confirmed partial response or better (i.e., PR, VGPR, CR, and sCR) based on IRC-assessment per IMWG criteria.

    Time frame: Up to approximately 407 weeks

  5. Complete Response Rate (CRR)

    Complete Response Rate (CRR), defined as the percentage of participants with a confirmed complete response (CR) or better (i.e., CR and stringent complete response (sCR)) based on IRC assessment per IMWG criteria.

    Time frame: Up to approximately 407 weeks

  6. Percentage of Participants With a Confirmed Very Good Partial Response (VGPR) or Better

    VGPR is defined as the percentage of participants with a confirmed VGPR or better (i.e., VGPR, CR, and sCR) based on IRC-assessment per IMWG criteria.

    Time frame: Up to approximately 407 weeks

  7. Time to Best Response (TTBR)

    Time to Best Response (TTBR) defined as the interval of time between the date of randomization and the earliest date of achieving best response among participants with a confirmed PR or better based on IRC-assessment per IMWG.

    Time frame: Up to approximately 407 weeks

  8. Time to Response (TTR)

    Time to Response (TTR) defined as the time between the date of randomization and the first documented evidence of response (PR or better) among participants who achieve a response (i.e., confirmed PR or better) based on IRC-assessment per IMWG.

    Time frame: Up to approximately 407 weeks

  9. Time to Progression (TTP)

    Time to Progression (TTP) defined as the time from randomization until the earliest date of PD based on IRC-assessment per IMWG criteria, or death due to PD.

    Time frame: Up to approximately 407 weeks

  10. Progression-free Survival on Subsequent Line of Therapy (PFS2)

    PFS2 defined as time from randomization to disease progression (investigator-assessed response) after initiation of new anti-myeloma therapy or death from any cause, whichever is earlier. If disease progression after new antimyeloma therapy cannot be measured, a PFS event is defined as the date of discontinuation of new anti-myeloma therapy, or death from any cause, whichever is earlier.

    Time frame: Up to approximately 407 weeks

  11. Number of Participants With Adverse Events (AEs)

    An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of a study treatment, whether or not considered related to the study treatment. AEs will be coded using the Medical Dictionary for Regulatory Activities (MedDRA dictionary).

    Time frame: Up to approximately 407 weeks

  12. Number of Participants With Clinically Significant Changes in Hematology Parameters

    Blood samples will be collected for the analysis of hematology parameters.

    Time frame: Up to approximately 407 weeks

  13. Number of Participants With Clinically Significant Changes in Clinical Chemistry Parameters

    Blood samples will be collected for the analysis of clinical chemistry parameters.

    Time frame: Up to approximately 407 weeks

  14. Number of Participants With Abnormal Ocular Findings on Ophthalmic Examination

    Time frame: Up to approximately 407 weeks

  15. Plasma Concentrations of Belantamab Mafodotin (ADC)

    Blood samples will be collected for PK analysis of belantamab mafodotin.

    Time frame: Up to approximately 407 weeks

  16. Plasma Concentrations of Monomethyl Auristatin-F With a Cysteine Linker (Cys-mcMMAF)

    Blood samples will be collected for PK analysis of belantamab mafodotin.

    Time frame: Up to approximately 407 weeks

  17. Area Under Plasma Concentration-time Curve (AUC) From Time 0 to the Time of the Last Quantifiable Concentration (C(Tlast)) [AUC (0-last)] for Pomalidomide

    Blood samples will be collected for PK analysis of Pomalidomide in combination with belantamab mafodotin and dexamethasone

    Time frame: Up to approximately 407 weeks

  18. Area Under Plasma Concentration-time Curve (AUC) From Time 0 to End of the Dosing Interval [AUC (0-tau)] for Pomalidomide

    Blood samples will be collected for PK analysis of Pomalidomide in combination with belantamab mafodotin and dexamethasone.

    Time frame: Up to approximately 407 weeks

  19. Maximum Concentration (Cmax) for Pomalidomide

    Blood samples will be collected for PK analysis of Pomalidomide in combination with belantamab mafodotin and dexamethasone.

    Time frame: Up to approximately 407 weeks

  20. Time of Cmax (Tmax) for Pomalidomide

    Blood samples will be collected for PK analysis of Pomalidomide in combination with belantamab mafodotin and dexamethasone.

    Time frame: Up to approximately 407 weeks

  21. Trough Concentration Prior to the Next Dose for Each Cycle (Ctrough) for Pomalidomide

    Blood samples will be collected for PK analysis of Pomalidomide in combination with belantamab mafodotin and dexamethasone.

    Time frame: Up to approximately 407 weeks

  22. Last Time Point Where the Concentration is Above the Limit of Quantification (Tlast) for Pomalidomide

    Blood samples will be collected for PK analysis of Pomalidomide in combination with belantamab mafodotin and dexamethasone.

    Time frame: Up to approximately 407 weeks

  23. Number of Participants With Positive Anti-drug Antibodies (ADAs) Against Belantamab Mafodotin

    Serum samples will be collected for the analysis of the presence of ADAs using validated immunoassays. All samples will be tested in screening assay, and positive samples will be further characterized for antibody titers.

    Time frame: Up to approximately 407 weeks

  24. Titers of ADAs Against Belantamab Mafodotin

    Serum samples will be collected for the analysis of the presence of ADAs using validated immunoassays. All samples will be further tested in screening assay, and positive samples will be further characterized for antibody titers.

    Time frame: Up to approximately 407 weeks

  25. Number of Participants With Maximum Post-baseline Changes in Patient-reported Outcome Version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) Scores for Each Item Attribute

    The PRO-CTCAE is a patient-reported outcome measure that was developed to evaluate symptomatic toxicities in patients in cancer clinical trials; it characterizes the frequency, severity, interference, and presence or absence of symptomatic toxicities. Responses ranges from 0 ("never," "none," "not at all," or "absent") to 4 ("almost constantly," "very severe," or "very much"), with a higher score indicating a higher frequency, severity, or interference of adverse events.

    Time frame: Up to approximately 407 weeks

  26. Change From Baseline in Health Related Quality of Life (HRQoL) as Measured by European Organization for Research and Treatment of Cancer Quality of Life Questionnaire 30-item Core Module (EORTC QLQ-C30)

    The EORTC QLQ-C30 includes 30-items with single and multi-item scales. These includes five functional scales (physical functioning \[PF\], role functioning \[RF\], cognitive functioning \[CF\], emotional functioning \[EF\] and social functioning \[SF\]), three symptom scales (fatigue, pain and nausea/vomiting \[N/V\]), a global health status (GHS)/ Quality-of-Life (QoL) scale, and six single items (constipation, diarrhoea, insomnia, dyspnoea, appetite loss \[AL\] and financial difficulties \[FD\]). Response options are 1 to 4. Scores are averaged and transformed to 0 to 100, a high score for functional scales/ GHS/QoL represent better functioning ability or health-related quality-of-life (HRQoL), whereas a high score for symptom scales/ single items represent significant symptomatology. Baseline is defined as latest pre-dose assessment (Day 1) with a non-missing value, including unscheduled visits. Change from Baseline is calculated by subtracting Baseline value from the post-dose visit value.

    Time frame: Baseline and up to approximately 407 weeks

  27. Change From Baseline in HRQoL as Measured by EORTC QLQ-20-item Multiple Myeloma Module (MY20)

    The EORTC Quality of Life Questionnaire 20-item Multiple Myeloma module (QLQMY20) is a supplement to the QLQ-C30 instrument used in participants with multiple myeloma. The individual component scores in the disease symptom domain are averaged and transformed linearly to a score ranging from 0 to 100. A high score for disease symptoms represents a high level of symptomatology or problems. A high score for Future Perspective and Body Image represents a high/healthy level of functioning. Baseline is defined as latest pre-dose assessment (Day 1) with a non-missing value, including unscheduled visits. Change from Baseline is calculated by subtracting Baseline value from the post-dose visit value.

    Time frame: Baseline and up to approximately 407 weeks

  28. Change From Baseline in HRQoL as Measured by EORTC Item Library 52 (IL52)

    The EORTC Quality of Life Questionnaire 20-item Multiple Myeloma module (QLQMY20) is a supplement to the QLQ-C30 instrument used in participants with multiple myeloma. For the EORTC IL52, disease symptoms domain of the QLQ-MY20 will be used for bone aches or pain, back pain, hip pain, arm or shoulder pain, chest pain, and pain increasing with activity. The individual component scores in the disease symptom domain are averaged and transformed linearly to a score ranging from 0 to 100. A high score for disease symptoms represents a high level of symptomatology or problems. Baseline is defined as latest pre-dose assessment (Day 1) with a non-missing value, including unscheduled visits. Change from Baseline is calculated by subtracting Baseline value from the post-dose visit value.

    Time frame: Baseline and up to approximately 407 weeks

07

Results

Posted Jun 11, 2025

Participant flow

This study enrolled a total of 12 Japanese participants and the analyses included 9 Japanese participants that had been previously enrolled in the global study for 207499 (NCT04484623), resulting in a total of 21 participants.

Participant flow — Overall Study
MilestoneBelantamab Mafodotin+Pomalidomide+DexamethasoneBortezomib + Pomalidomide + Dexamethasone
Started1011
Completed00
Not completed1011
Withdrew: Death21
Withdrew: Withdrawal by subject10
Withdrew: Ongoing710

Outcome measures

PrimaryProgression-Free Survival (PFS)

PFS is defined as time from randomization until earliest date of disease progression (PD), determined by Independent Review Committee (IRC), according to the International Myeloma Working Group (IMWG) Response Criteria, or death due to any cause. PD is defined as increase of \>=25% from lowest value in \>=1 of following (serum M-protein \[absolute increase \>=0.5 grams per deciliter {g/dL}\]; serum M-protein increase \>=1g/dL \[when lowest M-protein \>=5g/dL\]; urine M-protein \[absolute increase \>=200 milligrams per 24 hours {mg/24h}\]; participants without measurable serum \& urine M-protein levels, difference between involved \& uninvolved serum free light chains (sFLC) levels \[absolute increase \>10mg/dL\]; appearance of new lesion,\>=50% increase from nadir in Sum of the products of the maximal perpendicular diameters of measured lesions (SPD) of \>1 lesion, or \>=50% increase in longest diameter of previous lesion \>1 centimeter (cm) in short axis.

Time frame:
Up to approximately 120 weeks
Reported as:
Median · Months
Progression-Free Survival (PFS)
MonthsBelantamab Mafodotin+Pomalidomide+DexamethasoneBortezomib + Pomalidomide + Dexamethasone
Progression-Free Survival (PFS)NA (0.2 to NA)14.8 (1.9 to NA)
Statistical analysis
  • Belantamab Mafodotin+Pomalidomide+Dexamethasone vs Bortezomib + Pomalidomide + Dexamethasone · Hazard ratio (hr): 0.53 · 95% CI 0.10 to 2.78Hazard ratio was estimated using an unstratified Cox Proportional Hazard model with treatment arm as an explanatory variable.
SecondaryOverall Survival (OS)

Overall Survival (OS) defined as the interval of time from randomization to the date of death due to any cause.

Time frame:
Up to approximately 407 weeks

Results for this outcome have not been posted.

SecondaryDuration of Response (DoR)

Duration of Response (DoR) defined as the time from first documented evidence of partial response (PR) or better until progressive disease (PD) or death due to any cause. Response will be based on IRC-assessment per IMWG criteria.

Time frame:
Up to approximately 407 weeks

Results for this outcome have not been posted.

SecondaryMinimal Residual Disease (MRD) Negativity Rate

MRD negativity rate defined as the percentage of participants who achieve MRD negative status (as assessed by NGS at 10\^5 threshold) at least once during the time of confirmed CR or better response based on IRC-assessment per IMWG.

Time frame:
Up to approximately 407 weeks

Results for this outcome have not been posted.

SecondaryOverall Response Rate (ORR)

ORR is defined as the percentage of participants with a confirmed partial response or better (i.e., PR, VGPR, CR, and sCR) based on IRC-assessment per IMWG criteria.

Time frame:
Up to approximately 407 weeks

Results for this outcome have not been posted.

SecondaryComplete Response Rate (CRR)

Complete Response Rate (CRR), defined as the percentage of participants with a confirmed complete response (CR) or better (i.e., CR and stringent complete response (sCR)) based on IRC assessment per IMWG criteria.

Time frame:
Up to approximately 407 weeks

Results for this outcome have not been posted.

SecondaryPercentage of Participants With a Confirmed Very Good Partial Response (VGPR) or Better

VGPR is defined as the percentage of participants with a confirmed VGPR or better (i.e., VGPR, CR, and sCR) based on IRC-assessment per IMWG criteria.

Time frame:
Up to approximately 407 weeks

Results for this outcome have not been posted.

SecondaryTime to Best Response (TTBR)

Time to Best Response (TTBR) defined as the interval of time between the date of randomization and the earliest date of achieving best response among participants with a confirmed PR or better based on IRC-assessment per IMWG.

Time frame:
Up to approximately 407 weeks

Results for this outcome have not been posted.

SecondaryTime to Response (TTR)

Time to Response (TTR) defined as the time between the date of randomization and the first documented evidence of response (PR or better) among participants who achieve a response (i.e., confirmed PR or better) based on IRC-assessment per IMWG.

Time frame:
Up to approximately 407 weeks

Results for this outcome have not been posted.

SecondaryTime to Progression (TTP)

Time to Progression (TTP) defined as the time from randomization until the earliest date of PD based on IRC-assessment per IMWG criteria, or death due to PD.

Time frame:
Up to approximately 407 weeks

Results for this outcome have not been posted.

SecondaryProgression-free Survival on Subsequent Line of Therapy (PFS2)

PFS2 defined as time from randomization to disease progression (investigator-assessed response) after initiation of new anti-myeloma therapy or death from any cause, whichever is earlier. If disease progression after new antimyeloma therapy cannot be measured, a PFS event is defined as the date of discontinuation of new anti-myeloma therapy, or death from any cause, whichever is earlier.

Time frame:
Up to approximately 407 weeks

Results for this outcome have not been posted.

SecondaryNumber of Participants With Adverse Events (AEs)

An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of a study treatment, whether or not considered related to the study treatment. AEs will be coded using the Medical Dictionary for Regulatory Activities (MedDRA dictionary).

Time frame:
Up to approximately 407 weeks

Results for this outcome have not been posted.

SecondaryNumber of Participants With Clinically Significant Changes in Hematology Parameters

Blood samples will be collected for the analysis of hematology parameters.

Time frame:
Up to approximately 407 weeks

Results for this outcome have not been posted.

SecondaryNumber of Participants With Clinically Significant Changes in Clinical Chemistry Parameters

Blood samples will be collected for the analysis of clinical chemistry parameters.

Time frame:
Up to approximately 407 weeks

Results for this outcome have not been posted.

SecondaryNumber of Participants With Abnormal Ocular Findings on Ophthalmic Examination
Time frame:
Up to approximately 407 weeks

Results for this outcome have not been posted.

SecondaryPlasma Concentrations of Belantamab Mafodotin (ADC)

Blood samples will be collected for PK analysis of belantamab mafodotin.

Time frame:
Up to approximately 407 weeks

Results for this outcome have not been posted.

SecondaryPlasma Concentrations of Monomethyl Auristatin-F With a Cysteine Linker (Cys-mcMMAF)

Blood samples will be collected for PK analysis of belantamab mafodotin.

Time frame:
Up to approximately 407 weeks

Results for this outcome have not been posted.

SecondaryArea Under Plasma Concentration-time Curve (AUC) From Time 0 to the Time of the Last Quantifiable Concentration (C(Tlast)) [AUC (0-last)] for Pomalidomide

Blood samples will be collected for PK analysis of Pomalidomide in combination with belantamab mafodotin and dexamethasone

Time frame:
Up to approximately 407 weeks

Results for this outcome have not been posted.

SecondaryArea Under Plasma Concentration-time Curve (AUC) From Time 0 to End of the Dosing Interval [AUC (0-tau)] for Pomalidomide

Blood samples will be collected for PK analysis of Pomalidomide in combination with belantamab mafodotin and dexamethasone.

Time frame:
Up to approximately 407 weeks

Results for this outcome have not been posted.

SecondaryMaximum Concentration (Cmax) for Pomalidomide

Blood samples will be collected for PK analysis of Pomalidomide in combination with belantamab mafodotin and dexamethasone.

Time frame:
Up to approximately 407 weeks

Results for this outcome have not been posted.

SecondaryTime of Cmax (Tmax) for Pomalidomide

Blood samples will be collected for PK analysis of Pomalidomide in combination with belantamab mafodotin and dexamethasone.

Time frame:
Up to approximately 407 weeks

Results for this outcome have not been posted.

SecondaryTrough Concentration Prior to the Next Dose for Each Cycle (Ctrough) for Pomalidomide

Blood samples will be collected for PK analysis of Pomalidomide in combination with belantamab mafodotin and dexamethasone.

Time frame:
Up to approximately 407 weeks

Results for this outcome have not been posted.

SecondaryLast Time Point Where the Concentration is Above the Limit of Quantification (Tlast) for Pomalidomide

Blood samples will be collected for PK analysis of Pomalidomide in combination with belantamab mafodotin and dexamethasone.

Time frame:
Up to approximately 407 weeks

Results for this outcome have not been posted.

SecondaryNumber of Participants With Positive Anti-drug Antibodies (ADAs) Against Belantamab Mafodotin

Serum samples will be collected for the analysis of the presence of ADAs using validated immunoassays. All samples will be tested in screening assay, and positive samples will be further characterized for antibody titers.

Time frame:
Up to approximately 407 weeks

Results for this outcome have not been posted.

SecondaryTiters of ADAs Against Belantamab Mafodotin

Serum samples will be collected for the analysis of the presence of ADAs using validated immunoassays. All samples will be further tested in screening assay, and positive samples will be further characterized for antibody titers.

Time frame:
Up to approximately 407 weeks

Results for this outcome have not been posted.

SecondaryNumber of Participants With Maximum Post-baseline Changes in Patient-reported Outcome Version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) Scores for Each Item Attribute

The PRO-CTCAE is a patient-reported outcome measure that was developed to evaluate symptomatic toxicities in patients in cancer clinical trials; it characterizes the frequency, severity, interference, and presence or absence of symptomatic toxicities. Responses ranges from 0 ("never," "none," "not at all," or "absent") to 4 ("almost constantly," "very severe," or "very much"), with a higher score indicating a higher frequency, severity, or interference of adverse events.

Time frame:
Up to approximately 407 weeks

Results for this outcome have not been posted.

SecondaryChange From Baseline in Health Related Quality of Life (HRQoL) as Measured by European Organization for Research and Treatment of Cancer Quality of Life Questionnaire 30-item Core Module (EORTC QLQ-C30)

The EORTC QLQ-C30 includes 30-items with single and multi-item scales. These includes five functional scales (physical functioning \[PF\], role functioning \[RF\], cognitive functioning \[CF\], emotional functioning \[EF\] and social functioning \[SF\]), three symptom scales (fatigue, pain and nausea/vomiting \[N/V\]), a global health status (GHS)/ Quality-of-Life (QoL) scale, and six single items (constipation, diarrhoea, insomnia, dyspnoea, appetite loss \[AL\] and financial difficulties \[FD\]). Response options are 1 to 4. Scores are averaged and transformed to 0 to 100, a high score for functional scales/ GHS/QoL represent better functioning ability or health-related quality-of-life (HRQoL), whereas a high score for symptom scales/ single items represent significant symptomatology. Baseline is defined as latest pre-dose assessment (Day 1) with a non-missing value, including unscheduled visits. Change from Baseline is calculated by subtracting Baseline value from the post-dose visit value.

Time frame:
Baseline and up to approximately 407 weeks

Results for this outcome have not been posted.

SecondaryChange From Baseline in HRQoL as Measured by EORTC QLQ-20-item Multiple Myeloma Module (MY20)

The EORTC Quality of Life Questionnaire 20-item Multiple Myeloma module (QLQMY20) is a supplement to the QLQ-C30 instrument used in participants with multiple myeloma. The individual component scores in the disease symptom domain are averaged and transformed linearly to a score ranging from 0 to 100. A high score for disease symptoms represents a high level of symptomatology or problems. A high score for Future Perspective and Body Image represents a high/healthy level of functioning. Baseline is defined as latest pre-dose assessment (Day 1) with a non-missing value, including unscheduled visits. Change from Baseline is calculated by subtracting Baseline value from the post-dose visit value.

Time frame:
Baseline and up to approximately 407 weeks

Results for this outcome have not been posted.

SecondaryChange From Baseline in HRQoL as Measured by EORTC Item Library 52 (IL52)

The EORTC Quality of Life Questionnaire 20-item Multiple Myeloma module (QLQMY20) is a supplement to the QLQ-C30 instrument used in participants with multiple myeloma. For the EORTC IL52, disease symptoms domain of the QLQ-MY20 will be used for bone aches or pain, back pain, hip pain, arm or shoulder pain, chest pain, and pain increasing with activity. The individual component scores in the disease symptom domain are averaged and transformed linearly to a score ranging from 0 to 100. A high score for disease symptoms represents a high level of symptomatology or problems. Baseline is defined as latest pre-dose assessment (Day 1) with a non-missing value, including unscheduled visits. Change from Baseline is calculated by subtracting Baseline value from the post-dose visit value.

Time frame:
Baseline and up to approximately 407 weeks

Results for this outcome have not been posted.

Adverse events

Collected over All cause mortality, non-serious adverse events (Non-SAEs) and serious adverse events (SAEs) were collected up to approximately 120 weeks. The results presented are until the primary completion date. Additional results will be provided within a year of study completion.. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Belantamab Mafodotin+Pomalidomide+Dexamethasone2/10 (20%)5/10 (50%)10/10 (100%)
Bortezomib + Pomalidomide + Dexamethasone1/11 (9.1%)4/11 (36.4%)11/11 (100%)
Most frequent serious events
Showing 10 of 12
Most frequent serious events
EventBelantamab Mafodotin+Pomalidomide+DexamethasoneBortezomib + Pomalidomide + Dexamethasone
OedemaGeneral disorders1/100/11
CholelithiasisHepatobiliary disorders1/100/11
Cytomegalovirus chorioretinitisInfections and infestations1/100/11
Morganella infectionInfections and infestations1/100/11
Pneumocystis jirovecii pneumoniaInfections and infestations1/100/11
PneumoniaInfections and infestations1/101/11
Diabetic ketoacidosisMetabolism and nutrition disorders1/100/11
Normal pressure hydrocephalusNervous system disorders1/100/11
Sinus node dysfunctionCardiac disorders0/101/11
CataractEye disorders0/101/11
Most frequent other events
Showing 10 of 123
Most frequent other events
EventBelantamab Mafodotin+Pomalidomide+DexamethasoneBortezomib + Pomalidomide + Dexamethasone
Vision blurredEye disorders9/101/11
ConstipationGastrointestinal disorders5/107/11
Alanine aminotransferase increasedInvestigations6/102/11
Neutrophil count decreasedInvestigations3/105/11
Foreign body sensation in eyesEye disorders4/100/11
DiarrhoeaGastrointestinal disorders4/101/11
Aspartate aminotransferase increasedInvestigations4/101/11
ThrombocytopeniaBlood and lymphatic system disorders3/104/11
Oedema peripheralGeneral disorders1/104/11
Platelet count decreasedInvestigations3/104/11

Baseline characteristics

Age, Continuous
Age, Continuous(YEARS)Belantamab Mafodotin+Pomalidomide+DexamethasoneBortezomib + Pomalidomide + DexamethasoneTotal
Mean72.6 ± 5.9572.5 ± 5.7072.6 ± 5.67
Sex: Female, Male
Sex: Female, Male(Participants)Belantamab Mafodotin+Pomalidomide+DexamethasoneBortezomib + Pomalidomide + DexamethasoneTotal
Female6612
Male459
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Belantamab Mafodotin+Pomalidomide+DexamethasoneBortezomib + Pomalidomide + DexamethasoneTotal
Asian- Japanese Heritage101121
08

Study locations

13 sites
  • GSK Investigational Site
    Nagoya, Aichi-ken 467-8602, Japan
  • GSK Investigational Site
    Kamogawa, Chiba 296-8602, Japan
  • GSK Investigational Site
    Kashiwa, Chiba 277-8567, Japan
  • GSK Investigational Site
    Matsuyama, Ehime 790-8524, Japan
  • GSK Investigation Site
    Fukushima, Fukushima 960-1295, Japan
  • GSK Investigational Site
    Maebashi, Gunma 371-8511, Japan
  • GSK Investigational Site
    Shibukawa, Gunma 377-0280, Japan
  • GSK Investigational Site
    Numakunai, Iwate 028-3695, Japan
  • GSK Investigational Site
    Okayama, Okayama-ken 701-1192, Japan
  • GSK Investigational Site
    Osaka, Osaka 565-0871, Japan
  • GSK Investigational Site
    Tottori-shi, Tottori 683-8504, Japan
  • GSK Investigational Site
    Yamagata, Yamagata 990-9585, Japan
  • GSK Investigational Site
    Hokkaido, 060-8648, Japan
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No — GSK will assess requests from qualified researchers for anonymized individual patient-level data and related study documents. Data sharing is subject to certain criteria, conditions, and exceptions. For further information, refer to https://www.gsk-studyregister.com/gsk-patient-level-data-sharing-july2025.pdf

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Feb 2022 to primary completion in May 2024, 27 months.

Results were first posted in Jun 2025, 1 year after primary completion.

Of 107 industry-sponsored phase 3 interventional studies under Multiple Myeloma, half reached primary completion within 45 months of starting (the median), counting those still running; a quarter within 30 and three quarters within 66. This study's 27 months is below that.

Counting every sponsor, half of 179 studies reached it within 55 months; a quarter within 34 and three quarters within 95.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 25, 2025
First posted
May 4, 2025
StartActual
Feb 10, 2022
Primary completionActual
May 27, 2024
CompletionEst.
Jun 25, 2029
Results first posted
Jun 11, 2025
Last update
Jun 12, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 12, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT06956170
Lead sponsor
GlaxoSmithKline
Responsible party
Sponsor
First posted
May 4, 2025
Start date
Feb 10, 2022
Primary completion
May 27, 2024
Completion
Jun 25, 2029 (estimated)
Results posted
Jun 11, 2025
Last update
Jun 12, 2026

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in May 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Belantamab mafodotin

Start the discussion